A Phase 2 interventional study of Pemetrexed and Cetuximab in Head and Neck Neoplasms, sponsored by Eli Lilly and Company. Completed at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-19.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing pemetrexed in Head and Neck Neoplasms — 1 open to participants now, 1 under way, none of them phase 3. Pemetrexed · Head and Neck Neoplasms.
Among the 13 studies testing pemetrexed in Head and Neck Neoplasms, this one is the 3rd largest by enrollment, is one of 2 that started in 2010, is one of 8 in phase 2, and was the 9th registered.
2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.
Browse Head and Neck Neoplasms studies →1 of the 13 studies testing pemetrexed in Head and Neck Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 69 is above the median of 46 across 2,033 interventional studies indexed under Head and Neck Neoplasms.
Median enrollment 36 across the 13 interventional studies. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 13 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
14 studies in Head and Neck Neoplasms by Eli Lilly and Company: 1 open now, 3 under way, none of them phase 3. Of 11 finished, 9 (82%) have results posted.
Among the 14 studies in Head and Neck Neoplasms by Eli Lilly and Company, this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is one of 5 that started in 2010, is one of 7 in phase 2, and was the 8th registered.
Eli Lilly and Company’s Head and Neck Neoplasms studies by the year they started, since 2005.
1 of the studies testing pemetrexed in Head and Neck Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05358548Rutgers, The State University of New JerseyATATcH Alternating Treatment Plans for Advanced Cancer | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing pemetrexed in Head and Neck Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 14 in Head and Neck Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to look for an improvement in progression free survival with the combination of pemetrexed, carboplatin (or cisplatin) and cetuximab in participants with recurrent or metastatic squamous cell carcinoma of the head and neck.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Histologic or cytologic diagnosis of squamous cell head and neck cancer (HNC)
Prior therapies:
Adequate organ function as defined by the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cycle 1: Week 1 - Cetuximab 400 milligrams/square meter (mg/m²) on Day 1; Pemetrexed 500 mg/m² on Day 1; Carboplatin area under curve (AUC) 5 on Day 1 or Cisplatin 75 mg/m² on Day 1 Week 2 - Cetuximab 250 mg/m² on Day 1 Week 3 - Cetuximab 250 mg/m² on Day 1 Cycle 2-6: Week 1 - Cetuximab 250 mg/m² on Day 1; Pemetrexed 500 mg/m² on Day 1; Carboplatin AUC 5 on Day 1 or Cisplatin 75 mg/m² on Day 1 Week 2 - Cetuximab 250 mg/m² on Day 1 Week 3 - Cetuximab 250 mg/m² on Day 1 Following Cycle 6, Cetuximab Monotherapy: 250 mg/m² intravenously weekly on Day 1
Drug: Pemetrexed · Drug: Cetuximab · Drug: Carboplatin · Drug: Cisplatin
Administered intravenously, for maximum of 6 cycles.
Also known as: Alimta, LY231514
Administered intravenously in combination therapy, for a maximum of 6 cycles. After the completion of 6 cycles, participants who have not experienced disease progression will continue on cetuximab monotherapy until disease progression.
Also known as: Erbitux
Administered intravenously, for a maximum of 6 cycles
Administered intravenously, for a maximum of 6 cycles
Progression-Free Survival (PFS)
PFS was defined as the duration from the date of enrollment to the first date of documented objective progressive disease (PD) or death from any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. PD is ≥20% increase in sum of longest diameter of target lesions or the appearance of new lesions. For participants who were not known to have died or to have had objective PD at the time of the data inclusion cutoff, PFS was censored at their last objective progression-free disease assessment prior to the cutoff date or the date of initiation of subsequent systemic anticancer therapy.
Time frame: From enrollment to measured progressive disease up to 15.3 months (tumor assessments performed every other cycle during study treatment, and then every 6 weeks during follow-up)
Overall Survival (OS)
OS is defined as the duration from the date of enrollment to the date of death from any cause. For participants who were alive at the time of the data inclusion cutoff, OS was censored at the date of last contact prior to that cut-off date.
Time frame: From enrollment to the date of death from any cause up to 26.4 months (assessment completed during trial period at least every 3 months)
Percentage of Participants Having a Confirmed Partial Response (PR) or Complete Response (CR)
PR or CR is classified by the investigators according to RECIST criteria version 1.0. PR is a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesions; CR is the disappearance of all target and non-target lesions. Percentage of participants having a PR or CR is calculated as a total number of participants with PR or CR from enrollment until disease progression or recurrence divided by the total number of participants treated, then multiplied by 100.
Time frame: From enrollment to objectively determined progressive disease up to 15.3 months (tumor assessments performed every other cycle during study treatment until progressive disease)
Change From Baseline in Participant-Reported European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L)
EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. A regression equation defines a utility value for these health states to generate an index score. The possible values for index score range from -0.594 (severe problems in all 5 dimensions) to 1 (no problem in all dimensions) on a scale where 1 represents the best possible health state. The EQ-5D Visual Analog Scale (VAS) is used to record a participant's rating for his/her current health-related quality of life state on the day of questionnaire administration and is captured on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state).
Time frame: Baseline, Day 1 of Cycles 2, 4, 6, cetuximab monotherapy Cycles 2 and 4 (21-day cycle)
Change From Baseline in Performance Status Scale for Head and Neck Cancer (PSS-HNC)
PSS-HNC is a clinician-rated instrument designed to measure speaking and eating disabilities of participants with head and neck cancer and consists of 3 subscales: normalcy of diet (NOD) subscale measures the ability of the participants to eat a normal diet, subscale ranges from 0 (non-oral feeding) to 100 (unrestricted diet); understandability of speech (UOS) subscale measures the degree a clinician is able to understand the participant's speech, subscale ranges from 0 (never understandable) to 100 (always understandable); eating in public (EIP) subscale, rating based on the participant's response to the questions of whom he/she eats with and in what setting, subscale ranges from 0 (always eats alone) to 100 (no restriction of place, food, or companion). Change from baseline: negative value represents a decrease in function and a positive value represents an increase in function.
Time frame: Baseline, Day 1 of Cycles 2, 4, 6, cetuximab monotherapy Cycles 2 and 4 (21-day cycle)
Number of Participants Who Died While on Treatment and Died During 30-Day Post-Treatment Discontinuation Follow-Up (FU)
Presented are the number of participants who died due to adverse events (AEs) while on treatment and participants who died due to progressive disease (PD) during the 30-day post-treatment discontinuation FU.
Time frame: From enrollment to 30 days post-treatment discontinuation up to 26.4 months
| Milestone | Cetuximab + Pemetrexed + Carboplatin/Cisplatin |
|---|---|
| Started | 69 |
| Received ≥1 dose of any study drug | 69 |
| Completed 6 cycles | 69 |
| Efficacy population | 58 |
| Received carboplatin | 63 |
| Completed | 67 |
| Not completed | 2 |
| Withdrew: Protocol violation | 2 |
PFS was defined as the duration from the date of enrollment to the first date of documented objective progressive disease (PD) or death from any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.0. PD is ≥20% increase in sum of longest diameter of target lesions or the appearance of new lesions. For participants who were not known to have died or to have had objective PD at the time of the data inclusion cutoff, PFS was censored at their last objective progression-free disease assessment prior to the cutoff date or the date of initiation of subsequent systemic anticancer therapy.
| months | Cetuximab + Pemetrexed + Carboplatin/Cisplatin |
|---|---|
| Progression-Free Survival (PFS) | 5.1 (3.9 to 6.0) |
OS is defined as the duration from the date of enrollment to the date of death from any cause. For participants who were alive at the time of the data inclusion cutoff, OS was censored at the date of last contact prior to that cut-off date.
| months | Cetuximab + Pemetrexed + Carboplatin/Cisplatin |
|---|---|
| Overall Survival (OS) | 11.1 (7.6 to 14.8) |
PR or CR is classified by the investigators according to RECIST criteria version 1.0. PR is a ≥30% decrease in sum of longest diameter of target lesions without new lesion and progression of non-target lesions; CR is the disappearance of all target and non-target lesions. Percentage of participants having a PR or CR is calculated as a total number of participants with PR or CR from enrollment until disease progression or recurrence divided by the total number of participants treated, then multiplied by 100.
| percentage of participants | Cetuximab + Pemetrexed + Carboplatin/Cisplatin |
|---|---|
| Percentage of Participants Having a Confirmed Partial Response (PR) or Complete Response (CR) | 25.9 (15.3 to 39.0) |
EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. A regression equation defines a utility value for these health states to generate an index score. The possible values for index score range from -0.594 (severe problems in all 5 dimensions) to 1 (no problem in all dimensions) on a scale where 1 represents the best possible health state. The EQ-5D Visual Analog Scale (VAS) is used to record a participant's rating for his/her current health-related quality of life state on the day of questionnaire administration and is captured on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state).
| units on a scale | Cetuximab + Pemetrexed + Carboplatin/Cisplatin |
|---|---|
| Change in Index Score at Cycle 2 (n=43) | 0.038 ± 0.233 |
| Change in Index Score at Cycle 4 (n=29) | 0.070 ± 0.147 |
| Change in Index Score at Cycle 6 (n=24) | -0.063 ± 0.249 |
| Change in Index Score at monotherapy Cycle2 (n=14) | 0.016 ± 0.098 |
| Change in Index Score at monotherapy Cycle 4 (n=7) | 0.059 ± 0.080 |
| Change in VAS Score at Cycle 2 (n=41) | 3.854 ± 21.600 |
| Change in VAS Score at Cycle 4 (n=28) | 2.107 ± 24.894 |
| Change in VAS Score at Cycle 6 (n=21) | 0.333 ± 16.716 |
| Change in VAS Score at monotherapy Cycle 2 (n=14) | -1.500 ± 16.919 |
| Change in VAS Score at monotherapy Cycle 4 (n=7) | 0.571 ± 13.377 |
PSS-HNC is a clinician-rated instrument designed to measure speaking and eating disabilities of participants with head and neck cancer and consists of 3 subscales: normalcy of diet (NOD) subscale measures the ability of the participants to eat a normal diet, subscale ranges from 0 (non-oral feeding) to 100 (unrestricted diet); understandability of speech (UOS) subscale measures the degree a clinician is able to understand the participant's speech, subscale ranges from 0 (never understandable) to 100 (always understandable); eating in public (EIP) subscale, rating based on the participant's response to the questions of whom he/she eats with and in what setting, subscale ranges from 0 (always eats alone) to 100 (no restriction of place, food, or companion). Change from baseline: negative value represents a decrease in function and a positive value represents an increase in function.
| units on a scale | Cetuximab + Pemetrexed + Carboplatin/Cisplatin |
|---|---|
| Change in NOD at Cycle 2 (n=52) | 4.62 ± 18.63 |
| Change in UOS at Cycle 2 (n=52) | -2.40 ± 18.69 |
| change in EIP at Cycle 2 (n=52) | 2.88 ± 21.38 |
| Change in NOD at Cycle 4 (n=34) | 3.24 ± 24.58 |
| Change in UOS at Cycle 4 (n=35) | -0.71 ± 19.63 |
| Change in EIP at Cycle 4 (n=34) | -6.62 ± 24.08 |
| Change in NOD at Cycle 6 (n=28) | 9.29 ± 24.78 |
| Change in UOS at Cycle 6 (n=28) | -1.79 ± 16.57 |
| Change in EIP at Cycle 6 (n=28) | -1.79 ± 28.81 |
| Change in NOD at monotherapy Cycle 2 (n=16) | 11.88 ± 32.29 |
| Change in UOS at monotherapy Cycle 2 (n=16) | -4.69 ± 16.38 |
| Change in EIP at monotherapy Cycle 2 (n=17) | -4.41 ± 35.61 |
| Change in NOD at monotherapy Cycle 4 (n=9) | 8.89 ± 18.33 |
| Change in UOS at monotherapy Cycle 4 (n=9) | 2.78 ± 23.20 |
| Change in EIP at monotherapy Cycle 4 (n=9) | 2.78 ± 23.20 |
Presented are the number of participants who died due to adverse events (AEs) while on treatment and participants who died due to progressive disease (PD) during the 30-day post-treatment discontinuation FU.
| participants | Cetuximab + Pemetrexed + Carboplatin/Cisplatin |
|---|---|
| Due to AE while on treatment | 3 |
| Due to PD during 30-day FU | 5 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cetuximab + Pemetrexed + Carboplatin | — | 23/63 (36.5%) | 63/63 (100%) |
| Cetuximab + Pemetrexed + Cisplatin | — | 3/6 (50%) | 6/6 (100%) |
| Event | Cetuximab + Pemetrexed + Carboplatin | Cetuximab + Pemetrexed + Cisplatin |
|---|---|---|
| Myocardial infarctionCardiac disorders | 1/63 | 1/6 |
| VomitingGastrointestinal disorders | 1/63 | 1/6 |
| CachexiaMetabolism and nutrition disorders | 0/63 | 1/6 |
| DehydrationMetabolism and nutrition disorders | 2/63 | 1/6 |
| Febrile neutropeniaBlood and lymphatic system disorders | 4/63 | 0/6 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/63 | 0/6 |
| Urinary tract infectionInfections and infestations | 3/63 | 0/6 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 3/63 | 0/6 |
| AnaemiaBlood and lymphatic system disorders | 2/63 | 0/6 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/63 | 0/6 |
| Event | Cetuximab + Pemetrexed + Carboplatin | Cetuximab + Pemetrexed + Cisplatin |
|---|---|---|
| NauseaGastrointestinal disorders | 24/63 | 5/6 |
| FatigueGeneral disorders | 44/63 | 5/6 |
| VomitingGastrointestinal disorders | 10/63 | 4/6 |
| DehydrationMetabolism and nutrition disorders | 13/63 | 4/6 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 21/63 | 4/6 |
| AnaemiaBlood and lymphatic system disorders | 40/63 | 1/6 |
| ThrombocytopeniaBlood and lymphatic system disorders | 31/63 | 3/6 |
| DiarrhoeaGastrointestinal disorders | 17/63 | 3/6 |
| DyspepsiaGastrointestinal disorders | 1/63 | 3/6 |
| Mucosal inflammationGeneral disorders | 22/63 | 3/6 |
All enrolled participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Cetuximab + Pemetrexed + Carboplatin/Cisplatin |
|---|---|
| Mean | 61.9 ± 10.3 |
| Sex: Female, Male(Participants) | Cetuximab + Pemetrexed + Carboplatin/Cisplatin |
|---|---|
| Female | 12 |
| Male | 57 |
| Ethnicity (NIH/OMB)(Participants) | Cetuximab + Pemetrexed + Carboplatin/Cisplatin |
|---|---|
| Hispanic or Latino | 5 |
| Not Hispanic or Latino | 63 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Cetuximab + Pemetrexed + Carboplatin/Cisplatin |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 11 |
| White | 56 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Cetuximab + Pemetrexed + Carboplatin/Cisplatin |
|---|---|
| United States | 69 |
| European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L)(units on a scale) | Cetuximab + Pemetrexed + Carboplatin/Cisplatin |
|---|---|
| Index Score (n=47) | 0.721 ± 0.248 |
| Visual Analog Scale (VAS) Score (n=47) | 66.106 ± 20.658 |
| Performance Status Scale for Head and Neck Cancer (PSS-HNC)(units on a scale) | Cetuximab + Pemetrexed + Carboplatin/Cisplatin |
|---|---|
| NOD (n=57) | 56.32 ± 37.87 |
| UOS (n=57) | 78.51 ± 32.20 |
| EIP (n=57) | 71.93 ± 34.42 |
The record gives a start of Aug 2010, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemetrexed · Cetuximab · Carboplatin · Cisplatin